Investors Shareholders

About
Teams
Sustainability
Investments
Media

Important notice

Current portfolio

Eloxx Pharma

Developing Therapeutics to treat genetic diseases

Sector
Healthcare
Country
United States
Fund
LSP 5
Entry
2017
Web
eloxxpharma.com

Sector
Healthcare
Country
United States
Fund
LSP 5
Entry
2017
Web
eloxxpharma.com

Eloxx Pharma

Latest news

13 December 2024
EQT completes public offering of common stock of Kodiak Gas Services
13 December 2024
EQT Completes Acquisition of PropertyGuru
13 December 2024
EQT Exeter acquires two UK warehouses in Milton Keynes and Dartford
11 December 2024
EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million
06 December 2024
EQT Life Sciences leads Series A funding round for maternal health company Nua Surgical

0

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of news

Regulatory News

EQT News

Preferred languageEnglishSwedish

Email address

Offices

Europe
North America
- New York
- San Francisco
APAC

About

EQT Playbook
Fund investors
Purpose and Culture
EQT Foundation
- EQT Foundation
Careers
- Life at EQT
- EQT Academy
Motherbrain

Teams

Roles

Sustainability

Future-proofing

Business Segments

Private Capital
Real Assets

Investments

Portfolio

Shareholders

About EQT AB Group
IPO on Nasdaq Stockholm
Reports and Presentations
Corporate Governance
About the Share

Media

Newsroom
- News
- Reports and presentations

Contact

Media
- Press Contact
Follow

Legal

Sustainable Finance Disclosure
Complaints Handling Procedure
Glossary and Definitions
Policies
EQT Cookie Notice
Terms and Conditions

About

Teams

Sustainability

Investments

Shareholders

Media

Contact

Legal

A purpose-driven global investment organization

© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180